Skip to main
GUTS
GUTS logo

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc. is positioned favorably due to the significant rise in GLP-1 drug prescriptions, which surged 587% from 2019 to 2024, indicating a growing market for effective obesity and diabetes treatments. The company’s emphasis on developing durable disease-modifying therapies, demonstrated by promising results from the REMAIN-1 trial and advancements in their GLP-1 PGTx program, underscores its potential to outperform current treatment options. Additionally, the anticipated scalability of manufacturing capabilities will support increased production as clinical programs progress, potentially enhancing the company’s competitive standing in the metabolic therapeutics space.

Bears say

Fractyl Health's stock outlook appears negative due to concerns surrounding its high cash burn associated with expanding development and commercial programs, which may not be sustainable without sufficient capital or revenue from milestones. Additionally, research highlights that patients with type 2 diabetes (T2D) face a progressive decline in β-cell function, which complicates treatment efficacy and could hinder patient outcomes. Lastly, the observed lower efficacy of Fractyl's GLP-1 therapies compared to pharmacologic alternatives raises questions about the company's ability to effectively address the treatment needs of T2D patients, potentially impacting its competitive positioning in the market.

GUTS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.